BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low – Time to Sell?

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $8.00 and last traded at $7.9550, with a volume of 69323 shares. The stock had previously closed at $8.33.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Raymond James Financial upgraded shares of BridgeBio Oncology Therapeutics to a “moderate buy” rating in a report on Friday, January 9th. Weiss Ratings assumed coverage on shares of BridgeBio Oncology Therapeutics in a report on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Stifel Nicolaus assumed coverage on shares of BridgeBio Oncology Therapeutics in a report on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective on the stock. Finally, HC Wainwright increased their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a report on Friday, March 6th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.00.

BridgeBio Oncology Therapeutics Stock Down 2.5%

The stock’s fifty day moving average is $9.15. The firm has a market cap of $613.67 million, a price-to-earnings ratio of -5.04 and a beta of 0.22.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Several hedge funds have recently bought and sold shares of BBOT. CIBC Private Wealth Group LLC acquired a new stake in BridgeBio Oncology Therapeutics in the fourth quarter worth $63,000. Persistent Asset Partners Ltd acquired a new stake in BridgeBio Oncology Therapeutics in the fourth quarter worth $107,000. Squarepoint Ops LLC acquired a new stake in BridgeBio Oncology Therapeutics in the fourth quarter worth $144,000. Quadrature Capital Ltd acquired a new stake in BridgeBio Oncology Therapeutics in the fourth quarter worth $162,000. Finally, BIT Capital GmbH acquired a new stake in BridgeBio Oncology Therapeutics in the fourth quarter worth $313,000. 54.89% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.